pharma · Advanced solid tumors · Advanced Solid Tumors · TTRX
Turn Therapeutics
Turn Therapeutics (Nasdaq: is a pharma organization headquartered in Westlake Village, USA. It trades on NYSE under ticker TTRX. Primary therapeutic focus areas include Advanced solid tumors, Advanced Solid Tumors, Covid
Westlake Village, USA HQ
2015 Founded
11 Employees
Public company Type
TTRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Westlake Village, USA
- Founded
- 2015
- Employees
- 11
- Programs
- 6
- Drugs
- 3
- Patents
- 40
CA177-1036
Phase 1 · other · Phase 1: Advanced solid tumors harboring genetic alterations in MET
CA177-1036 for Phase 1: Advanced solid tumors harboring genetic alterations in MET is a Phase 1 program (other) at Turn Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CA177-1036
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Turn Therapeutics
- Phase
- Phase 1
- Modality
- other
- Indication
- Phase 1: Advanced solid tumors harboring genetic alterations in MET
- Status
- active
- Trials
- 1